Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.
Each presenter will then answer questions from a panel of investors and pharma partnering leaders.
Dinner Reception and Networking on the Terrace
2017 Speakers Dinner (by invite only)
Scientific Session 1: Peptides in the Clinic
Updates on clinical development of peptide therapeutics.
Poster Session View Poster Abstracts
Meienhofer Award Presentation
Networking and Dinner
Scientific Session 2: Drug Delivery
Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies
Abstract: For small companies, early stage drug development is risky and assigned little tangible value by investors. It is, however, a necessary step that must be taken before moving into human proof-of-concept trials, where programs begin to attain value, real investment and momentum toward becoming a commercial therapy. In a virtual model, peptide programs can go from molecule selection through safety studies and a first-in-human clinical trial in less than 2 years and less than $2M. Key to that speed and cost-efficiency is right-sizing the CMC effort to provide the needed API, drug product, test methods, release criteria and stability program, without over-investing before knowing if the program has commercial viability. The panel will discuss different strategies of how to right-size peptide programs, balance the risks and timing for CMC support activities, discuss pros and cons of early vs late investment in formulation and analytical methods, and provide real-world examples.
Lisa Caralli is Senior Director of Pharmaceutics at Catalent San Diego. She has over 25 years of industry experience in pharmaceutical research and development. Lisa's area of expertise is analytical methods and formulation development of small molecules and peptides. Currently, she has a role in Catalent’s Science and Technology team where she works with pharmaceutical companies to identify the right development pathway for their early development drug candidates. Prior to joining the San Diego site over 12 years ago, Lisa was an Analytical Project Manager at Isis Pharmaceuticals where she worked on the chemistry, manufacturing and controls of antisense (oligonucleotide) drugs. Lisa joined Isis from Amylin Pharmaceuticals where she directed their amino acid analysis core facility and performed methods development for peptide-drug candidates. She began her career at the Immune Response Corporation studying biological markers of autoimmune diseases. Lisa holds a B.S. in Biochemistry from the University of California at Davis.
Daron Evans is currently Managing Director of PoC Capital, LLC, a fund making direct investments into proof-of-concept clinical trials. He also serves as a Director for Zumbro Discovery and CEO of Nephros, Inc. From 2007 to 2013, Mr. Evans served as CFO of Nile Therapeutics (now Capricor). Previously, he worked at multiple Johnson & Johnson companies, co-founded of Applied Neuronal Network Dynamics, and served in various roles at the consulting firms Arthur D. Little and Booz Allen & Hamilton. Mr. Evans received his B.S. in Chemical Engineering from Rice University, his M.S. in Biomedical Engineering from a joint program at the University of Texas at Arlington and Southwestern Medical School and his MBA from the Fuqua School of Business at Duke University.
Dave Garman is currently the Chief Technology Officer for NoNO Inc, a biotechnology company directed at the development of novel peptide therapeutics to treat neurological disorders with unmet medical needs. His roles have encompassed most aspects of the development of a peptide therapeutic for the treatment of stroke from initial animal results in the laboratory through Phase 3 clinical trials. Dr. Garman’s primary responsibilities include all aspects of manufacturing, quality and regulatory interactions related to CMC, preclinical safety pharmacology and toxicity assessment of peptide therapeutics, intellectual property development and the development of both next generation and novel peptide therapeutics for the company pipeline.
Prior to joining NoNO Inc, Dr. Garman worked for 11 years at Arbor Vita Corporation, where he held roles from Scientist through Vice President, Business Development. His primary roles included working with the Arbor Vita team on the development of a medium throughput peptide:protein interaction platform to examine the selectively of peptide inhibitors. He also worked on the development of specific peptides for both clinical diagnostic and therapeutic uses.
Dinner on Own
Meeting of the Scientific Advisory Board (closed session)
Chemistry of Complex Peptides
Lunch and Farewell Reception
Boxed lunches will be provided